MYCN and neuroblastoma: Since RTA-408 is not a selective inhibitor of KLHL37, in the future, it would be beneficial to develop specific protein-protein interaction inhibitors that target the unique interface of the KLHL37–N-Myc complex, offering patients with neuroblastoma better therapeutic drug options.